SJÖGREN’S · International recommendations
Why Sjögren recommendations differ between countries
How to use guidelines without losing sight of your own symptoms and goals
Different recommendations do not necessarily mean that one clinician has missed the answer. Documents may address different symptoms, include different studies or reflect medicines available in a particular country. The useful question is which recommendation fits your situation and what improvement the proposed treatment is meant to achieve.
What is a guideline?
A clinical guideline brings research together with judgments about benefits, harms and what is practical in care. It helps a clinician and patient choose a plan; it is not an individual prescription. The evidence is stronger for some questions than for others, particularly when a complication is rare. [R01] [R02]
First identify the job of the treatment: preventing damage to the eye surface or new cavities, reducing inflammatory joint problems, protecting lung or nerve function, or making daily activities easier. A medicine that helps one of these goals may do little for another. Two recommendations can therefore differ because they are answering different questions. [R01] [R02]
Which documents are being compared?
The documents below cover different patients and different parts of care. Their names and dates help explain why their medicine lists do not match.
- EULAR, the European Alliance of Associations for Rheumatology, provides a broad framework for local treatment and treatment acting throughout the body. Its recommendations were issued in 2019. [R02]
- BSR, the British Society for Rheumatology, covers adult and juvenile disease. This guideline was published in 2024. [R01]
- The US Sjögren’s Foundation has separate guidance for rheumatologic manifestations (2017), prevention of tooth decay (2016), lung disease (2021), and peripheral nerve problems (2026). A nerve guideline is not a replacement for a dental guideline. [R03] [R04] [R05] [R06]
- The Brazilian Society of Rheumatology has guidance focused on skin and blood manifestations (2024), and neurologic, cognitive and psychiatric manifestations (2025). [R09] [R10]
- The Chinese off-label treatment guideline concerns adults and medicines used for purposes outside their approved labeling. Its English edition was published in 2025. Japan has a 2025 edition of its Sjögren guideline. [R07] [R08]
- Some recommendations cover several rheumatic diseases. Examples are the EULAR 2024 update on medicines in reproduction, pregnancy and breastfeeding and the 2026 ERS/EULAR lung guideline. ERS is the European Respiratory Society; the latter document addresses interstitial lung disease, which affects the lung tissue around the air sacs. [R14] [R88]
The publication year is not the last date of the research reviewed. For example, the Chinese guideline searched databases through 31 December 2022. Later studies may change the discussion, but do not become part of an older guideline automatically. Check both the document’s scope and its evidence dates. [R07]
Does “conditional” mean the treatment is poor?
A conditional recommendation means the best choice may depend on the person’s circumstances, preferences and tolerance of risk, or that the evidence is uncertain. It does not mean the treatment is necessarily poor. A strong recommendation is not a promise that every patient will benefit. [R01] [R02]
The certainty of evidence and the strength of a recommendation describe different things. Evidence certainty describes how reliable the estimates of benefit and harm are. Recommendation strength also takes account of their balance and the circumstances of care. A high percentage of agreement among experts is not the percentage of patients who improved. [R01] [R07]
Ask what benefit is realistic for you, what the downsides and alternatives are, when the result and side effects will be reviewed, and what would justify continuing treatment. A medicine’s absence from a guideline may reflect its publication date or purpose; it does not by itself establish that the medicine is prohibited or effective.
Why eye and mouth care remain central
Eye and mouth care are active treatment. Replacing moisture, stimulating remaining saliva production and preventing damage have different jobs. Fluoride helps prevent tooth decay; saliva substitutes mainly improve comfort. Eye treatment should reflect the condition of the eye surface as well as how dry it feels. [R02] [R04] [R17]
Symptoms and damage do not always move together. A comfortable mouth can still be at risk of cavities. Eyes may need protection even when they do not hurt much. A treatment plan therefore needs both symptom relief and checks for damage. [R02] [R04]
A formulation update matters here: on 15 October 2026, the US Food and Drug Administration (FDA) approved EVOXAC oral solution, containing cevimeline, for dry-mouth symptoms in adults with Sjögren’s. A liquid may be useful for someone who has difficulty swallowing capsules. The manufacturer announced expected US availability by the end of 2026; approval does not establish that a local pharmacy already has it. This treats dry-mouth symptoms. The approval does not establish control of inflammation throughout the body or regeneration of damaged glands. [R84] [R85]
Why is hydroxychloroquine still discussed?
Hydroxychloroquine (HCQ) remains an option for selected inflammatory or systemic manifestations. Systemic disease activity refers to active manifestations that a clinician assesses using an established scale; it is not a score of how exhausted or dry someone feels. HCQ has not been shown to reliably relieve dryness, fatigue and pain for everyone. In JOQUER, HCQ was compared for 24 weeks with placebo, a treatment without the active drug used for comparison. The main outcome was at least a 30% improvement in at least two of three symptoms: dryness, pain and fatigue. HCQ did not outperform placebo on this outcome. [R01] [R02] [R03] [R20]
A trial of HCQ needs a stated purpose and a review point. Continuing simply because the medicine is commonly used is unhelpful. Equally, a negative trial summary is not enough reason to stop a prescription without understanding why it was chosen in your case. The clinician should explain how benefit and medication-specific side effects will be checked. [R01] [R03]
NECESSITY adds new evidence, but concerns combinations rather than HCQ alone. The abstract presented at the 2026 American College of Rheumatology (ACR) conference described 211 participants. At week 24, 24.3% receiving placebo, 54.4% receiving HCQ plus mycophenolate mofetil, and 52.4% receiving HCQ plus leflunomide met the STAR response definition. STAR combines several measurements into one trial response; those percentages do not mean that each person’s dryness, pain and fatigue all improved. [R83]
The clearest difference was in participants with a high symptom burden and low systemic activity. Results in the smaller cohort with more systemic activity, and results using CRESS, another combined response measure, were not statistically significant. That does not establish that benefit is confined to one group. Serious adverse events were reported more often with HCQ plus mycophenolate mofetil. This difference alone does not prove that the combination caused those events. A conference abstract needs fuller publication and assessment of patient selection, benefits and safety before these combinations can be treated as routine symptom treatment. [R83]
Does severe fatigue require stronger immune treatment?
Fatigue can be severe even when measured inflammation is low. It deserves assessment and treatment. Sleep problems, anemia, thyroid disease, pain, medication effects, emotional strain and loss of physical conditioning can contribute alongside Sjögren’s. Checking these possibilities is part of taking fatigue seriously. [R01] [R45]
Agree on something meaningful to track: finishing a household task, preparing a meal, or recovering after an outing. If treatment improves organ inflammation but fatigue remains, the fatigue plan still needs attention. Persistent fatigue alone does not show that stronger immune treatment will help. [R01] [R45]
Why are stronger medicines used for some organs?
Inflammatory lung disease, vasculitis (inflammation of blood vessels), and some forms of neuropathy (nerve damage or dysfunction) can threaten organ function. They may need prompt treatment that reduces immune activity. Evidence that a medicine failed to improve general symptoms does not answer every organ question. For example, negative rituximab trials for dryness or fatigue do not exclude a role in selected serious organ complications. [R02] [R05] [R06] [R21]
The discussion should name the organ, show the evidence of active inflammation, and distinguish it from lasting damage or another cause. It should also state the expected benefit and how harm will be monitored. A goal such as preserving lung function or preventing further nerve loss makes the reason for treatment understandable. [R02] [R05] [R06] [R88]
Are medicines used in another country better?
A different medicine list may reflect availability, clinical practice and different judgments about limited evidence. The Chinese guideline discusses systemic combinations, iguratimod and standardized plant-derived preparations used less often in other countries. It also discusses tacrolimus for difficult-to-treat immune thrombocytopenia, a low platelet count caused by immune activity. These are specific treatment questions, not evidence that a country’s whole approach is superior. [R07]
Off-label means using an authorized medicine for an indication, dose or other purpose outside its local approved labeling. It is different from using a product that is not authorized in that country at all. A guideline recommendation, local drug authorization and proof of benefit for a particular symptom are separate questions. Some recommendations rest on small or observational studies; those limits still matter when a medicine is familiar locally. [R07]
The same plant name does not ensure the same ingredients, purity or dose. An imported mixture cannot be assumed to be the standardized product studied. Before considering a treatment from another country, identify the exact product, the problem it is intended to treat, the quality of the evidence, its risks and its local authorization status. [R07]
What can we say about Japan and other regions?
Japan’s 2025 edition is the current Japanese guideline described here. Its full Japanese text is available through the official Minds guideline library, posted there on 5 November 2026. The English-language guideline titled ‘2017’, published in 2018, remains an older document and should not be presented as the latest Japanese edition. Access to a translation does not determine how current the recommendations are. [R08] [R89]
Brazilian organ-specific guidelines and the Korean KISS cohort also contribute useful information. A cohort follows patients over time; it is not a randomized comparison of treatments or a national guideline. The KISS work helps describe different symptom patterns and their course. Limited visibility in English does not mean that a region has no clinical knowledge, and different types of evidence should not be treated as interchangeable. [R09] [R10] [R16]
Why can pregnancy advice differ?
Pregnancy advice may address three separate questions: which medicines are compatible with pregnancy, how to control the mother’s disease, and how to monitor the baby’s heart. The American College of Rheumatology (ACR) reproductive guideline and the Society for Maternal-Fetal Medicine (SMFM) pregnancy guideline do not take the same approach to routine heart screening when anti-Ro/SSA or anti-La/SSB antibodies are present. SMFM’s document specifically concerns pregnancy with lupus. [R13] [R15]
ACR conditionally recommends repeated fetal echocardiography—ultrasound of the baby’s heart—with the schedule influenced by whether a previous baby was affected by neonatal lupus, a condition related to maternal antibodies, or heart block, a problem with the heart’s electrical conduction. SMFM advises against routinely repeating fetal echocardiograms solely to assess the PR interval outside a clinical trial. The PR interval concerns conduction of the heart’s electrical signal. That recommendation is not a ban on all fetal heart assessment. The scope of the question and the limited evidence help explain the difference. [R13] [R15]
Your plan should say which monitoring approach the team is using and why, taking your antibody results and pregnancy history into account. A medicine being compatible with pregnancy does not prove that it prevents every fetal complication. Discuss medication changes with the rheumatology and pregnancy teams. More detail is in Nutrition and special populations. [R13] [R14] [R15]
Does a new trial immediately change standard care?
A trial result, authorization for a particular indication, inclusion in a guideline and availability in a pharmacy are separate steps. Regulatory review itself does not mean approval. ‘Breakthrough Therapy’ designation is intended to speed drug development and review; it is not approval for routine use. A successful study still needs to be read for whom it enrolled, what improved, how large the benefit was and what harms occurred. [R43]
The full NEPTUNUS publication in October 2026 found a modest average advantage for monthly ianalumab on systemic disease activity, but did not establish benefit on the key symptom outcomes. In the November 2026 report of OASIZ-301, which randomized 648 participants, dazodalibep improved systemic disease activity, and treatment every four weeks also improved patient-reported dryness. This does not establish separate benefits for pain and fatigue. Improvement in a clinician’s assessment of disease activity and improvement in a person’s daily symptoms need to be examined separately. [R80] [R81]
New findings can also stop a program. On 8 October 2026, argenx announced that the phase 3 UNITY trial of efgartigimod would stop after an independent review concluded it could not meet its main efficacy goal. This is called stopping for futility. The announcement reported no new safety signal; the reason given was lack of the required efficacy result. [R82]
According to Novartis, as of November 19, 2026, the application to approve ianalumab for Sjögren’s disease is under FDA review. For trial details and the stage of individual medicines, see What clinical trials show and New treatments: stages and evidence. The distinction between changing immune activity and restoring gland function is discussed in Mechanisms, biomarkers and gland regeneration. [R87]
Four questions for a useful treatment plan
- What specific symptom, organ problem or risk are we trying to improve?
- How similar is my situation to that of the people in the studies behind this recommendation?
- What will we measure, when will we review it, and how will we check side effects?
- What would lead us to continue, adjust or stop the treatment?
Keep a short record of symptoms, daily function, examination or test findings, and treatment effects. Include possible side effects. Agree which symptoms need an earlier call, whether laboratory or other safety checks are needed, and who will review the results.
The plan can combine eye and dental protection, symptom treatment and treatment for an affected organ. One guideline or one medicine does not have to cover every problem. Treatment goals and response and Treatment by organ explain how those parts fit together.
Sources
- [R01] BSR guideline: adult and juvenile onset Sjögren disease (online 2024; issue 2025)
- [R02] EULAR recommendations: topical and systemic therapies (2019; published 2020)
- [R03] Carsons et al. US treatment guidelines for rheumatologic manifestations (2017)
- [R04] Zero et al. Oral management guideline: dental caries prevention (2016)
- [R05] Lee et al. Consensus guidelines for pulmonary disease in Sjögren (2021)
- [R06] Deboo et al. Peripheral nervous system manifestations guideline (2026)
- [R07] Mo et al. Chinese off-label treatment guideline, English edition (online 2025; issue 2026)
- [R08] Japan College of Rheumatology: Sjögren guideline 2025 edition
Additional source records
https://minds.jcqhc.or.jp/summary/c00906/ - [R09] Brazilian Society of Rheumatology: neurologic, cognitive and psychiatric manifestations (2025)
- [R10] Brazilian Society of Rheumatology: cutaneous and hematological manifestations (2024)
- [R13] ACR reproductive health guideline (2020)
Additional source records
https://acrjournals.onlinelibrary.wiley.com/doi/full/10.1002/art.41191 - [R14] EULAR reproductive medication recommendations: 2024 update (published 2025)
- [R15] SMFM Consult Series 64: SLE in pregnancy (2023; reaffirmed 2025)
- [R16] Korean KISS cohort: longitudinal patient symptom clusters (2021)
- [R17] Sjögren Foundation guideline authors: New Treatment Guidelines for Sjögren’s Disease (2016)
Additional source records
https://pubmed.ncbi.nlm.nih.gov/27431353/ - [R20] Gottenberg et al. Hydroxychloroquine: JOQUER randomized trial (2014)
- [R21] Bowman et al. Rituximab: TRACTISS randomized trial (2017)
- [R29] Amgen: OASIZ 301 positive topline announcement (22 September 2026)
- [R41] ClinicalTrials.gov: named late-stage Sjögren programs
Additional source records
https://clinicaltrials.gov/study/NCT05349214https://clinicaltrials.gov/study/NCT06104124https://clinicaltrials.gov/study/NCT06245408https://clinicaltrials.gov/study/NCT05673993https://clinicaltrials.gov/study/NCT07404865https://clinicaltrials.gov/study/NCT04968912https://clinicaltrials.gov/study/NCT06741969https://clinicaltrials.gov/study/NCT05817669https://clinicaltrials.gov/study/NCT07760818https://clinicaltrials.gov/study/NCT03905525https://clinicaltrials.gov/study/NCT04035668https://clinicaltrials.gov/study/NCT03100942https://clinicaltrials.gov/study/NCT02446249 - [R43] Novartis: FDA Breakthrough Therapy designation for ianalumab (16 January 2026)
- [R45] EULAR recommendations for management of fatigue in inflammatory rheumatic diseases (2023)
- [R80] NEPTUNUS-1/2: randomized phase III trials, NEJM (21 October 2026)
- [R81] Amgen: OASIZ-301 numerical phase III results (11 November 2026)
- [R82] argenx: phase III UNITY stopped for futility (8 October 2026)
Additional source records
https://argenx.com/news/2026/press-release-3376934.html - [R83] Mariette et al. NECESSITY: ACR 2026 abstract LB15
- [R84] FDA: EVOXAC oral solution approval letter, NDA 221183 (15 October 2026)
- [R85] Cosette: EVOXAC oral solution and expected US availability (20 October 2026)
- [R87] Novartis: ianalumab under FDA review for Sjögren’s disease (Meet Novartis Management, November 19, 2026, slide 25); related press release, November 10, 2026
- [R88] ERS/EULAR clinical practice guidelines for connective tissue disease-associated interstitial lung disease (2026).
Additional source records
https://pubmed.ncbi.nlm.nih.gov/40907995/ - [R89] Sumida et al. Clinical practice guideline for Sjögren’s syndrome 2017 (English publication, 2018).
Additional source records
https://minds.jcqhc.or.jp/summary/e00055/
Personal educational publication by Olga Goodman, MD. This is not a clinic portal or an emergency service. Any private expert service is separate from clinic accounts and insurance billing. Reuse requires attribution and a link to the original publication.